Curriculum: MS Pharm Sci: Health Outcomes & Pharmacoeconomics

December 15, 2022
33
January 09, 2023
  • This field is for validation purposes and should be left unchanged.

Application Fees Are Waived for Spring 2023

Click Here to Apply Today!

Get Your Questions Answered Here!

Join Program Director Dr. Ana Hincapie and Enrollment Services Advisor Abby Sparks as they talk about the Master's in Health Outcomes and Pharmacoeconomics degree at University of Cincinnati Online.

curriculum icon Curriculum at a Glance

For the Master of Science in Health Outcomes & Pharmacoeconomics online, the curriculum includes a total of 33 required semester credit hours to satisfy degree requirements. The curriculum is customizable and students can choose their courses.

Below is a sample curriculum. Please note, this is subject to change based on university discretion. The proposed schedule is a guide and is subject to change based on curriculum modifications and faculty availability.

Have questions? Speak with an Enrollment Advisor today!
Course Title / Description Credit
PCEU 7010
BIostatistics & Research Methods
Course: PCEU 7010
Credit: 3
The course begins with basic statistical concepts, introduces essential descriptive and inferential statistical tests, demonstrates some data analysis tools and collection instruments, then discusses common research methodology for pharmaceutical and cosmetic sciences. Students will learn how to use statistics and research designs to evaluate scientific evidence to make individual and population-based decisions. Students will conduct some simple statistical analysis based on given data sets and interpret the results, as well review clinical research literature.
3
PCEU 7050
Ethics in Scientific Research- Pharmacy
Course: PCEU 7050
Credit: 1
Students will learn about the various ethical and moral issues that are often encountered in scientific research including ways to identify and analyze them in the practice of research. The course is designed as an option to meet the NIH and NSF requirements for training in RCR (Responsible conduct of research). Topics to be covered include: RCR principles and guidelines, mentorship, collaborative research, conflict of interests, authorship and plagiarism, intellectual property and data handling, research involving human and animal subjects, scientific integrity and misconduct and social responsibility.
1
PHDD 8080
Pharmaceutical Economics and Management
Course: PHDD 8080
Credit: 3
This course will provide students a background in project management issues in the conduct of global clinical trials, financial aspects of drug development and pharmacoeconomics of approved drug/drug products. The first module will focus on logistic and strategic issues of project management encountered in modern drug development. It includes exposure to principles of project management of complex programs involving: pharmaceutical development, operations, and regulatory affairs. In addition, the corporate challenges involved with portfolio management and optimization will be presented focusing on tools used for optimum decision making. This knowledge base will be applied towards selective case presentations with the goal to identify critical decision points in the process that dramatically impact the successful launch of a new product. The second module will emphasize the business and financial aspects of drug development, including biotechnology and other innovative small pharmaceutical companies that derive their funding primarily from venture capital funding, business strategies, outsourcing and merger and acquisitions. Valuation of the new chemical/molecule as it evolves in the drug development pipeline will be discussed.
3
PHDD 8091
Drug Development Project I
Course: PHDD 8091
Credit: 2
This is the first of a two-course sequence. The overall objective is for the students to undertake a comprehensive study and/or participate in case studies that blend all the key concepts of didactic coursework in the program and demonstrate acquired competency in the application of the multi-disciplinary contemporary issues impacting development of new drugs, biologicals and devices, post-marketing surveillance/pharmacovigilance, health outcomes and optimizing drug therapy.
2
PHDD 8092
Drug Development Project II
Course: PHDD 8092
Credit: 2
This course follows Drug Development Project I and is the second course of a two part series. The overall objective is for the students to continue to undertake a comprehensive study and/or participate in case studies that blend all the key concepts of didactic coursework in the program and demonstrate acquired competency in the application of the multi-disciplinary contemporary issues impacting development of new drugs, biologicals and devices, post-marketing surveillance/pharmacovigilance, health outcomes and optimizing drug therapy. At the end of the study, the student may be required to prepare a manuscript and present a seminar as an "oral defense" that will be open to all students and faculty.
2
PHDD 8050
Phase I/II Clinical Trials Research and Design
Course: PHDD 8050
Credit: 3
This course will provide an understanding on the early clinical drug development activities for newchemical entity that has received IND approval. Concepts of early clinical pharmacology studies, typically conducted in a Phase I setting such as single and multiple dose pharmacokinetics, dose escalation studies to determine the safety and tolerability of drug, mass balance and drug metabolism studies and bioavailability studies will be taught. Emphasis will then be placed on Phase II trials as proof-of-principle, and on the dose-ranging requirements for Phase II. Trial designs including cross-over and parallel group will be discussed. The importance of Phase I/II trials for making dose selections for Phase III will be explored, as will the use of Phase II trials as a go/no-go decision point. The importance of exposure-response (PK/PD) information in guiding the go/no-go decision will also be discussed. The use of biomarkers and pharmacogenomic information in decision making will be addressed. Activities which run in parallel to PhaseI/II trials, including formulation development and clinical supplies and toxicology studies will be discussed.
3
PHDD 8080
Pharmaceutical Economics and Management
Course: PHDD 8080
Credit: 3
This course will provide students a background in project management issues in the conduct of global clinical trials, financial aspects of drug development and pharmacoeconomics of approved drug/drug products. The first module will focus on logistic and strategic issues of project management encountered in modern drug development. It includes exposure to principles of project management of complex programs involving: pharmaceutical development, operations, and regulatory affairs. In addition, the corporate challenges involved with portfolio management and optimization will be presented focusing on tools used for optimum decision making. This knowledge base will be applied towards selective case presentations with the goal to identify critical decision points in the process that dramatically impact the successful launch of a new product. The second module will emphasize the business and financial aspects of drug development, including biotechnology and other innovative small pharmaceutical companies that derive their funding primarily from venture capital funding, business strategies, outsourcing and merger and acquisitions. Valuation of the new chemical/molecule as it evolves in the drug development pipeline will be discussed.
3
PHDD 8070
Phase III/IV Clinical Trials and Research
Course: PHDD 8070
Credit: 3
This course will provide a comprehensive background in the design and conduct of large, multicenter Phase III clinical trials of investigational compounds. Emphasis will be placedon the conduct of studies that include patients with varying demographics (age, gender, genetic background and disease state such as renal and hepatic). Issues pertaining to clinical operations, project management, human subjects protections and data safety monitoring will be discussed. An introduction to principles of population pharmacokinetics and pharmacodynamics will be included. The course will include conceptsof post marketing surveillance of approved drugs for drug safety and idiosyncratic reactions, global approaches for pharmacovigilance and compliance with ICH guidelines for recording and dissemination of adverse events. Issues pertainingto pharmacoepidemiology and clinical utilization/effectiveness of the drug will also bediscussed.
3
PCEU 7040
Scientific Communication in Pharmacy
Course: PCEU 7040
Credit: 3
Scientific Communication in Pharmacy prepares you for your Capstone project by mastering specific techniques to make your scientific writing clearer for your audience and to meet the conventions of the scientific community. At the end of the term, you will be prepared to professionally communicate your future Capstone work by producing a journal ready paper. Throughout the semester, we will spend time drafting, revising, and finalizing such a paper. Your final written paper should demonstrate that you have mastered the conventions of scientific communication, clear writing, and proper style.
3
HI 7072
Leveraging Analytics and Business Intelligence Tools for Healthcare
Course: HI 7072
Credit: 3
This course will introduce students to a variety of cutting edge analytics and business intelligence tools applicable to health or healthcare data. Both structured and unstructured data will be introduced in this course. The coursewill also address topics related to data governance and data quality and various other topics relevant to health data management. This course is predominately hands-on and students willcomplete a project to demonstrate skills acquired.Students will learn how other industries have applied similar or the same tools.
3
PHDD 8010
Global Regulatory and Development Strategies of Drugs and Medical Devices
Course: PHDD 8010
Credit: 3
This course provides graduate students with an overview on legal and regulatory aspects relevant to drug and medical device development. This includes intellectual properties protection, global legal and regulatory requirements, protection of human subjects and ethics in clinical research and essential elements of management of global projects. Case studies will be included to underline how regulatory strategiesimpact product marketing and life cycle management. Throughout the course, students will integrate knowledge using specific industry examples with the goal to identify critical decision points in the development that impact success of a new drug or medical device on the market.
3
BANA 7015
Advanced Health Care Data Analytics, Business Intelligence and Reporting
Course: BANA 7015
Credit: 3
This course teaches the use of healthcare data to make decisions and transform healthcare delivery and the health of individuals and populations. The course concentrates on big and small data, and structured and unstructured data. Tools, applications and approaches for health data analytics are taught. This course covers topics such as statistical approaches; data, web and textmining; data visualization, simulation, modeling and forecasting. Key regulatory health and healthcare reporting requirements are taught.
3
Pharmcoeconomics and Decision Analytical Modeling
Course:
Credit: 3

This course is designed to provide an understanding of the theory and application of economic evaluation methods used in healthcare decision-making. Various methods such as cost-effectiveness analysis, cost-utility analysis, cost-minimization analysis, and cost-benefit analysis will be discussed to evaluate healthcare services, pharmaceuticals, and medical device products. Additionally, techniques to measure costs and outcomes will be discussed in detail along with assigning the monetary value to outcomes. Different types of models such as decision trees and Markov models will be taught. Students will have a chance to conduct independent group projects using a decision-analytic software package by which they will be able to conduct a cost-effectiveness analysis to compare different therapeutic options

3
Use of Real-World Data in Health Outcomes Research
Course:
Credit: 3

The objective of this graduate course is to prepare students to evaluate outcomes, comparative effectiveness, and health services research using real-world data (RWD). In this course, students will learn about the contents and structure of typical secondary healthcare databases used to perform outcomes, comparative effectiveness, and health services research, discuss the relative advantages and disadvantages of RWD data and identify methodological challenges of using RWD.

3
PHDD 8070
Phase III/IV Clinical Trials and Research
Course: PHDD 8070
Credit: 3
This course will provide a comprehensive background in the design and conduct of large, multicenter Phase III clinical trials of investigational compounds. Emphasis will be placedon the conduct of studies that include patients with varying demographics (age, gender, genetic background and disease state such as renal and hepatic). Issues pertaining to clinical operations, project management, human subjects protections and data safety monitoring will be discussed. An introduction to principles of population pharmacokinetics and pharmacodynamics will be included. The course will include conceptsof post marketing surveillance of approved drugs for drug safety and idiosyncratic reactions, global approaches for pharmacovigilance and compliance with ICH guidelines for recording and dissemination of adverse events. Issues pertainingto pharmacoepidemiology and clinical utilization/effectiveness of the drug will also bediscussed.
3
HCA 7001
Health Systems Management 1: Organization & Delivery
Course: HCA 7001
Credit: 3
The course is intended to provide the Master of Health Administration (MHA) student and future manager with a systems perspective of US health and health care structure and function. As the introductory course in the MHA program, it is to provide the fundamentals for all courses that follow, including finance and economics, strategy, quality improvement, policy and law, and others. Topics include an overview of the history, organization, and effectiveness of United States health care and public health systems, health system governance structures, roles, responsibilities as well as determinants of health, need, access and utilization.
3
HI 7030
Health Information Legislation, Privacy and Security
Course: HI 7030
Credit: 3
This course introduces legislation relevant to electronic health information privacy and information security. Topics such as electronic health information privacy and security safeguards, risk assessment methodology and contingency planning are taught. Students learn how to mitigate risk to business continuity and plan for disaster recovery.
3
HI7010
Health Informatics, Information Systems and Technology
Course: HI7010
Credit: 3
This course introduces the discipline of health informatics and covers emerging trends. Various information systems, technologies and applications utilized in the context of health and healthcare are introduced. Their characteristics, strengths, challenges, purpose and impact are taught. Impact on patients, populations and healthcare providers is emphasized. Factors influencing adoption and use of various clinical and health information systems and technologies are taught. Key information technologies and systems such as electronic health records, health information exchanges, personal health records, public health information systems and mobile health technologies are introduced in this course. Topics such as telemedicine, interoperability and technical concepts are taught, and evaluation framework is introduced.
3
Back to Top